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OBJECTIVE: Chronic heart failure (CHF) is a disease
with a poor prognosis leading to incapacitating symptoms
with recurrent hospital admissions. The MEtoprolol
CR/XL Randomized Intervention Trial in congestive
Heart Failure (MERIT-HF) was terminated early due to
the decrease in mortality in the patient group receiving
additional to standard treatment Metoprol CR/XL
(MET). The aim of the presented study is to show the eco-
nomic besides the clinical beneﬁt. METHODS: A cost
beneﬁt approach was used based on published data of
hospitalisation days from the multicentre randomized
double-blind placebo-controlled MERIT-HF and on the
additional drug costs as calculated based on the trial. The
calculation was done from the German payers’ perspec-
tive, only direct costs were taken into account. Data on
drug costs were derived from the Ifap-Index (2003), dis-
counts from retail pharmacists, whole salers manufac-
turers and patients’ co-payments were taken into
consideration. Daily bed charges for hospital stay were
taken from the database of German private health insur-
ers. Two scenarios were calculated. First it was assumed
that no patient stayed in an intensive care unit (ICU).
Second it was assumed each patient admitted to a hospi-
tal stayed at least one day in an ICU. RESULTS: In the
MET-group (1990 patients) a decrease of 2090 hospital-
isation days was seen compared to the placebo-group
(2001). The adjusted costs for the prevented hospital
stays were €499,555 (normal ward) or €558,109 (addi-
tional ICU). According to MERIT HF additional treat-
ment costs are €524,782 maximum. This result is highly
sensitive to the mean duration of treatment. If the “real-
istic” treatment duration is only 5% (26 days) below the
maximum of 521 days the costs will be €474,621 and
offset the hospitalisation costs. CONCLUSION: The 
presented data were calculated conservatively but prove
that the clinical beneﬁt is mirrored by the economic
results for the German health care system. Nevertheless,
further analysis on the detailed MERIT-HF data is
needed.
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OBJECTIVES: Estimate the cost-effectiveness ratio of
treating high vascular risk patients with simvastatin in
France. METHODS: Data were extracted from the pub-
lished results of the MRC/BHF Heart Protection Study
(HPS) performed in UK. HPS compared the occurrence
of total and CHD deaths, major vascular events (MVE),
and major coronary events (MCE) in more than 20,000
high vascular risk patients (patients with diabetes, prior
stroke or other cerebrovascular disease, peripheral 
arterial disease, or with CHD). Patients were randomly
assigned to simvastatin (40mg/day) or placebo and fol-
lowed at least for 5 years. The cost-effectiveness analysis
was performed using French unit costs. Direct costs
included the extra costs of simvastatin and the beneﬁt
associated with avoided vascular events. Indirect costs
were not considered. Costs and beneﬁt were discounted
at 5%. RESULTS: All-cause mortality was reduced by
13% (RR = 0.87, p = 0.0003). There was a discounted
survival beneﬁt of 0.040 year per included patient. There
were highly signiﬁcant reductions of about one quarter in
the risk of ﬁrst event rate of MVE (RR = 0.76, p < 0.0001)
and of MCE (RR = 0.73, p = 0.0001). The absolute reduc-
tion of events during the 5-year period in the simvastatin
group was 5.4% for any major vascular event, 2.1% for
non fatal MI, 1.3% for non fatal stroke, 2.4 % for revas-
cularisation, 1.2% for fatal MI and 0.2% for fatal stroke.
The discounted extra cost of simvastatin was estimated
at €1994 ($1 = €1) taking into account the statins in the
placebo group. This cost was reduced to €1031 by con-
sidering the direct cost associated with avoided vascular
events. Cost-effectiveness ratio was then estimated at
€25,517 per life year gained (€22,000 to €50,000 in the
different patients subcategories, ratios well accepted as
being cost-effective). CONCLUSION: Treatment with
simvastatin in different subcategories of high vascular risk
patients is cost-effective in the French setting.
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OBJECTIVES: To evaluate the cost effectiveness of the
low-molecular-weight heparin enoxaparin 40mg once
daily (ENOX) relative to no pharmacological prophylaxis
(NPP) and to unfractionated heparin 5000 IU thrice 
daily (UFH) in the prevention of venous thromboembolic
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events (VTE) in immobilized acutely ill general medical
inpatients from the hospital perspective in Germany.
METHODS: The incremental cost-effectiveness ratios
“additional cost for ENOX per clinical VTE averted
versus NPP” and “additional cost for ENOX per episode
of severe bleeding (ESB) averted versus UFH” were quan-
tiﬁed using a modelling approach based on decision-tree
technique. Resource use during thromboprophylaxis,
diagnosis, and treatment was collected from a hospital
survey. Costs were exclusively those to hospitals and were
determined by multiplying utilised resource items by the
price or tariff of each item. Clinical effectiveness was
taken from the MEDENOX [Samama et al. NEJM 1999]
and Thromboembolism-Prevention in Cardiac or Respi-
ratory Disease With Enoxaparin [Kleber et al. Am Heart
J 2003] trials and from a meta-analysis [Mismetti et al.
Thromb Haemost 2000]. The evaluation encompassed 8
(6–14) days of thromboprophylaxis plus time to treat
VTE and ESB in hospital. RESULTS: The base-case analy-
sis revealed incremental cost of €1543 for ENOX per clin-
ical VTE averted versus NPP, whereas ENOX dominated
UFH. In comprehensive sensitivity analyses, using impact
analysis and Monte Carlo simulation, the robustness of
the model was shown. In no case had the price of ENOX
the main impact on cost effectiveness. In 95% of 10,000
simulation steps, incremental cost for ENOX ranged
between €201 and 4 €154 per clinical VTE averted versus
NPP. In 91% of 10,000 simulation steps, ENOX
remained dominant over UFH. CONCLUSIONS: In
acutely ill general medical inpatients, ENOX offers 
hospitals in Germany a highly cost-effective thrombo-
prophylaxis compared to NPP and an enormous saving
potential when used instead of UFH.
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OBJECTIVES: Cardiovascular death is an important
endpoint in clinical trials. In health-economic analyses it
also plays a key role in the calculation of the number of
life years gained. Unlike other outcomes like myocardial
infarction (MI) or stroke, not much research has been
done on the assessment of speciﬁc resource use in patients
dying of a cardiovascular cause. This study assessed the
cost of cardiovascular death in Belgium. METHODS: In
this cost-of-illness study, data on resource utilisation were
retrospectively collected in patients with a history of MI
who died in the hospital in the year 2002. Four hospitals
were selected based on setting (community-university)
and geographical region (north and south). Direct
medical costs from the health care payer’s perspective, as
expressed by the intensity of medical resource consump-
tion in physical units, times the direct cost or charge per
unit, were considered. Costs were deﬁned as cost of hos-
pitalisation (basic care and nursing), drug use, diagnostic
tests, physician consults and technical interventions.
RESULTS: The charts of 60 patients were reviewed (mean
age: 76 ± 11 years). The average length of stay was 5.28
days (St. Err. 0.64). The main causes of death were MI
(37%), cardiogenic shock (22%) and ventricular ﬁbrilla-
tion (20%). The average hospitalisation cost €2045 (St.
Err. €215), the drug cost €383 (St. Err. €97), the cost of
diagnostic tests €344 (St. Err. €42), the cost of physician
consults €29 (St. Err. €7) and the cost of technical inter-
ventions €943 (St. Err. €207), resulting in a total cost 
of death from cardiovascular disease of €3744 (St. Err.
€431). In the Northern part the average cost is about
€1000 higher compared to the Southern part (€4284 vs.
€3239) (NS). CONCLUSIONS: Cardiovascular death 
is not only an important clinical endpoint but also an
important economic parameter due to its high cost.
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OBJECTIVE: Results from the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) study
showed that clopidogrel plus aspirin, comparing to
aspirin alone, reduced the cardiovascular events (death,
myocardial infarction, and stroke) in patients with acute
coronary syndromes (ACS). Yet the acquisition cost of
clopidogrel is much higher. It would therefore be worth-
while to compare the long term cost impact of these 2
regimens. METHODS: Until recently, only very few
patients with ACS received a clopidogrel-aspirin combi-
nation therapy in Hong Kong. Therefore a hypothetical
cohort was formed and compared to a real group of
patients treated with aspirin alone. For the aspirin group,
medical history was reviewed and cardiovascular and gas-
trointestinal events occurring in a period of 12 months
after initiation of therapy were recorded. The target cost
items included hospitalisation, emergency room visits,
outpatient clinic visits, related medications, diagnostic
tests, procedures and surgery. For the hypothetical
cohort, the probabilities/relative risks for clinical events
were adopted from the CURE study. The unit cost of
drugs and other resource items were based on the Hong
Kong Hospital Authority drug acquisition cost 2001 and
Hong Kong Government Gazette 2003 respectively. The
perspective of the study was that of a public health organ-
isation. RESULTS: Fifty-four consecutive patients with
ACS receiving aspirin therapy were identiﬁed over the
period of January 1, 2001 to December 31, 2001 from 
a major public hospital in Hong Kong and studied. 
